Cancer Immune Therapy Edited by G. Stuhler and P. Walden ...
Cancer Immune Therapy Edited by G. Stuhler and P. Walden ...
Cancer Immune Therapy Edited by G. Stuhler and P. Walden ...
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
404 Index<br />
nucleic acids, cancer immunotherapy 268ff.<br />
NY-ESO, antigen 48<br />
o<br />
ODC see ornithine decarboxylase<br />
ODN see oligodeoxynucleotides<br />
oligodeoxynucleotides (ODN), bacterial<br />
immunotherapy 269±277<br />
oncogenic mutations 206ff.<br />
ornithine decarboxylase (ODC) 133<br />
ovarian cancer<br />
±, clinical trials 190<br />
±, T-body approach 294<br />
over-expressed cellular proteins 231<br />
p<br />
PA28, proteasome activator 31±36<br />
palindromes, bacterial immunotherapy 269<br />
pancreas cancer, clinical trials 191<br />
PAP see prostatic acid phosphatase<br />
papillomavirus oncoproteins 209<br />
pattern recognition receptors (PRR), CpG<br />
motif 271f.<br />
PBLs see peripheral blood lymphocytes<br />
PBMC, specific CTL monitoring 44ff.<br />
PCR see polymerase chain reaction<br />
pCTL see CTL precursor<br />
PE see pseudomonas exotoxin<br />
PE38 360f., 367f.<br />
pediatric solid tumors, clinical trials 191<br />
PEGylation see polyethylene glycol<br />
peptide library approach, combinatorial 44<br />
peptide specificity, antigen-specific T cell<br />
responses 3<br />
peptide vaccination 234<br />
peptide/HLA tetramers see HLA/peptide<br />
tetramer responses<br />
peptides<br />
±, antigenic 254f.<br />
±, complexes with HSP 257±260<br />
±, HCV 240<br />
±, latency-associated 119<br />
±, MHC class II-associated Ii 62<br />
±, multiple epitopes 187<br />
pER-CEA<br />
±, immunocytokines 320, 325f.<br />
peripheral blood lymphocytes (PBLs) 304<br />
peripheral lymphoid-like tissues 333f.<br />
peripheral tolerance<br />
±, contributions of HSPs 263<br />
±, T cells 319<br />
±, to self antigens 220<br />
peritumoral lymphoid tissue 334<br />
PG E2 see prostagl<strong>and</strong>in<br />
phage antibody libraries 364<br />
phenotype-genotype link 363f.<br />
phosphatidylinositol 3-kinase, IL-10 157<br />
phosphodiester DNA backbone (PO), ODN<br />
classes 272ff.<br />
phosphorothioate (PS), DNA backbone 272f.<br />
plant toxins, immunotoxins 351f.<br />
plasmacytoid monocytes 179f.<br />
plasmacytoid morphology, dendritic cells 179<br />
PO see phosphodiester DNA backbone<br />
pokeweed antiviral protein, immunotoxins<br />
352<br />
polyamines<br />
±, immunosuppressive factors 120, 132ff.<br />
polyethylene glycol (PEGylation), immunotoxins<br />
368<br />
polymerase chain reaction (PCR) 64<br />
±, reverse-transcription 110<br />
polynucleotides, bacterial immunotherapy<br />
268ff.<br />
polytopes, dendritic cells 187<br />
PRAME, tumor associated antigen 36, 43<br />
preclinical development, immunotoxins 358f.<br />
preclinical experimental models, T bodies<br />
292f.<br />
preclinical studies, HCV 237f.<br />
preventive cancer vaccines 12, 232<br />
preventive immunotherapy 12<br />
primary antibody libraries 364<br />
prognostic value, IL-10 163f.<br />
prostagl<strong>and</strong>in (PG) E2<br />
±, immunosuppressive factors 120, 131f.<br />
prostagl<strong>and</strong>ins, macrophages 107<br />
prostate cancer 327ff.<br />
±, clinical trials 190, 193<br />
prostate-specific antigen (PSA) 293<br />
±, dendritic cells 195<br />
prostate-specific membrane antigen (PSMA)<br />
193, 293<br />
prostatic acid phosphatase (PAP) 193<br />
proteasomes<br />
±, antigen processing 59f.<br />
±, immuno 31±37, 43<br />
protein tyrosine kinases (PTKs) 288<br />
proteins<br />
±, antibody-cytokine fusion 311f.<br />
±, ch14.18-IL-2 fusion 330±341<br />
±, folate binding 292ff.<br />
±, glyco- 351<br />
±, gp70 envelope 316<br />
±, heat shock see heat shock proteins<br />
±, HSP/peptide fusion 260<br />
±, latent TGF-b binding 119ff.<br />
±, lymphotoxin (LT)-a fusion 313
Change language